Drug-induced thrombocytopenia (DIT) is a rare adverse effect that occurs when administering various medications. The medications associated with this possible adverse effect include heparin, penicillin, furosemide, vancomycin, non-steroidal anti-inflammatory drugs, ranitidine, and many others. DIT causes a rapid decrease in platelet counts after drug administration and typically resolves once the offending agent has been discontinued. The induced thrombocytopenia increases the bleeding risk and possibility of adverse effects throughout a hospital course. In this case report, we look at the presenting symptoms and treatment course of an interesting case of DIT that occurred following the administration of vancomycin.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423590PMC
http://dx.doi.org/10.7759/cureus.41874DOI Listing

Publication Analysis

Top Keywords

drug-induced thrombocytopenia
8
thrombocytopenia case
4
case involving
4
involving vancomycin
4
vancomycin drug-induced
4
thrombocytopenia dit
4
dit rare
4
rare adverse
4
adverse occurs
4
occurs administering
4

Similar Publications

Incidence and risk factors of Vancomycin-induced thrombocytopenia: a six-year real-world study.

BMC Infect Dis

January 2025

Department of Pharmacy, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application Beijing Hospital, Beijing, 100730, P.R. China.

Objectives: Drug-induced thrombocytopenia has been reported for numerous drugs. Vancomycin-induced thrombocytopenia (VIT) is infrequently and often under-recognized. VIT can lead to the serious consequences of some life-threatening bleeding, especially in high-risk population.

View Article and Find Full Text PDF

It is unclear whether drugs other than warfarin can cause spontaneous gastrointestinal intraluminal hematomas (SGIH). This study aimed to investigate the drugs that induced SGIH based on the FDA Adverse Event Reporting System (FAERS) data. A retrospective pharmacovigilance study was conducted.

View Article and Find Full Text PDF

Olanzapine, a second-generation antipsychotic widely used for schizophrenia, is primarily known for its efficacy in managing both positive and negative symptoms. While its metabolic side effects are well-documented, hematologic complications such as thrombocytopenia are rare and often underrecognized. A 30-year-old Middle Eastern male with a longstanding history of schizophrenia developed persistent thrombocytopenia after several years of olanzapine use, with platelet counts consistently below the normal range.

View Article and Find Full Text PDF

Background: Thrombocytopenia, defined as a platelet count of less than 150 × 10/L, is a frequent condition among hospitalized patients and presents unique challenges in diagnosis and management. Despite its commonality, data on incidence and related risk factors in medical inpatients remain limited, especially in older people.

Methods: A 2-year prospective cohort study with a 3-year follow-up was conducted on inpatients aged ≥65 years admitted to a medical ward.

View Article and Find Full Text PDF

Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease-induced and treatment-related cytopenias. Venetoclax, a selective BCL-2 inhibitor, in combination with azacitidine, a hypomethylating agent, is currently being investigated in patients with previously untreated higher-risk MDS.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!